Keywords
Chronic disease
Genes
Metabolic syndrome
Cardiovascular Diseases
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To carry out a study related to four polymorphisms in genes that may be associated with the Metabolic Syndrome. Methods: A systematic review was carried out based on the PRISMA method, with the approval number CRD42022375987 by PROSPERO, in which PubMed databases were used with the appropriate descriptors. Results: The presence of the SNP rs8050136 in the FTO gene may indicate a high association with the process of increasing body mass index, overweight and diabetes, being a polymorphism to be considered in MetS. In general, TCF7L2 is a gene to be considered in Metabolic Syndrome (MetS), as the SNP rs7901695 has been associated with the development of type 2 diabetes mellitus and MetS, and rs12255372 is a candidate for the development of personalized treatment for people with this polymorphism and can be considered a biomarker. As for the ADRB3 gene, the GG allelic form of the rs4994 SNP had no significant association with MetS when presented alone, only when associated with other polymorphisms. Final considerations: All SNPs studied may have a strong association with MetS, especially with regard to the rs8050136 and rs12255372 polymorphisms, but further studies are needed in more heterogeneous populations for these polymorphisms.
References
BOIKO AS, et al. Search for Possible Associations of FTO Gene Polymorphic Variants with Metabolic Syndrome, Obesity and Body Mass Index in Schizophrenia Patients. Pharmacogenomics and personalized medicine, 2021; 14: 1123-1131.
BOVOLINI A, et al. Metabolic syndrome pathophysiology and predisposing factors. International Journal of Sports Medicine, 2021; 42(03): 199-214.
CASTRO-BARQUERO S, et al. Dietary strategies for metabolic syndrome: a comprehensive review. Nutrients, 2020; 12(10): 2983-3003.
DEL BOSQUE-PLATA L, et al. The role of TCF7L2 in type 2 diabetes. Diabetes, 2021; 70(6): 1220-1228.
GBD 2015 OBESITY COLLABORATORS. Health effects of overweight and obesity in 195 countries over 25 years. New England journal of medicine, 2017; 377(1): 13-27.
GU Z, et al. FTO polymorphisms are associated with metabolic dysfunction-associated fatty liver disease (MAFLD) susceptibility in the older Chinese Han population. Clinical Interventions in Aging, 2020; 15: 1333-1341.
HAMEED T, et al. Associations of transcription factor 7-Like 2 (TCF7L2) gene polymorphism in patients of type 2 diabetes mellitus from Khyber Pakhtunkhwa population of Pakistan. African Health Sciences, 2021; 21(1): 15-22.
HUANG C, et al. Studies on the fat mass and obesity-associated (FTO) gene and its impact on obesity-associated diseases. Genes & Diseases, 2022.
JIA G, et al. N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nature chemical biology, 2011; 7(12): 885-887.
JMEL H, et al. Pharmacogenetic landscape of Metabolic Syndrome components drug response in Tunisia and comparison with worldwide populations. PLoS One, 2018; 13(4): e0194842.
KATSOULIS K, et al. TCF7L2 gene variants predispose to the development of type 2 diabetes mellitus among individuals with metabolic syndrome. Hormones, 2018; 17(3): 359-365.
LIMA ACD DE, et al. Alterações sensoriais em respiradores orais: revisão sistemática baseada no método prisma. Revista Paulista de Pediatria, 2019; 37(1): 97-103.
LIN JR, et al. Brown adipocyte ADRB3 mediates cardioprotection via suppressing exosomal iNOS. Circulation Research, 2022; 131(2): 133-147.
LIU Y, et al. Metabolic syndrome‐related SNPs in HLA and TNF7L2 may be risk factors for generalized pustular psoriasis in Chinese Han population. Skin Health and Disease, 2021; 1(2): e18.
MORAES TI. Relação entre polimorfismos dos genes LEP, FTO, APOA5, ADRB3, TCF7L2, ENPP1, CYP11B2 e PPARG e a síndrome metabólica. Dissertação (Mestrado em Ciências Farmacêuticas) – Faculdade de Ciências Farmacêuticas. Universidade de São Paulo, São Paulo, 2015.
NAGRANI R, et al. Common genetic variation in obesity, lipid transfer genes and risk of Metabolic Syndrome: Results from IDEFICS/I. Family study and meta-analysis. Scientific reports, v. 10, n. 1, p. 1-14, 2020; 89p.
ORGANIZAÇÃO MUNDIAL DA SAÚDE (OMS). The top 10 causes of death. Disponível em: <https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death>. Acessado em: 19 de setembro de 2022.
PAGE MJ, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ, 2021; 372: e71.
RAFAQAT S, et al. Biomarkers of Metabolic Syndrome: Role in Pathogenesis and Pathophysiology of Atrial Fibrillation. Journal of Atrial Fibrillation, 2021; 14(2): e20200495.
SAKLAYEN MG. The global epidemic of the metabolic syndrome. Current hypertension reports, 2018; 20(2): 1-8.
SAMSON SL e GARBER AJ. Metabolic syndrome. Endocrin and Metabolism Clinics, 2014; 43(1): 1-23.
SAUCEDO R, et al. Gene variants in the FTO gene are associated with adiponectin and TNF-alpha levels in gestational diabetes mellitus. Diabetology & Metabolic Syndrome, 2017; 9(1): 1-7.
SEDAGHATI-KHAYAT B, et al. Lack of association between FTO gene variations and metabolic healthy obese (MHO) phenotype: Tehran Cardio-metabolic Genetic Study (TCGS). Eating and Weight Disorders-Studies on Anorexia, Bulimia and Obesity, 2020; 25(1): 25-35.
SRIKANTHAN K, et al. Systematic review of metabolic syndrome biomarkers: a panel for early detection, management, and risk stratification in the West Virginian population. International journal of medical sciences, 2017; 13(1): 25-38.
TINAJERO MG e MALIK VS. An Update on the Epidemiology of Type 2 Diabetes. Endocrinology and Metabolism Clinics of North America, 2021; 50(3): 337-355.
VELAZQUEZ-ROMAN J, et al. Association of FTO, ABCA1, ADRB3, and PPARG variants with obesity, type 2 diabetes, and metabolic syndrome in a Northwest Mexican adult population. Journal of Diabetes and its Complications, 2021; 35(11): e108025.
YAZDI KV, et al. SLC30A8, CDKAL1, TCF7L2, KCNQ1 and IGF2BP2 are associated with type 2 diabetes mellitus in Iranian patients. Diabetes, metabolic syndrome and obesity: targets and therapy, 2020; 13: 897-906.
ZAFAR U, et al. Adrenergic receptor beta-3 rs4994 (T> C) and liver X receptor alpha rs12221497 (G> A) polymorphism in Pakistanis with metabolic syndrome. Chinese Journal of Physiology, 2019; 62(5): 196-202.
ZHAO X, et al. FTO-dependent demethylation of N6-methyladenosine regulates mRNA splicing and is required for adipogenesis. Cell research, 2014; 24(12): 1403-1419.